{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:17:29Z","timestamp":1764829049522,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"KAKENIHI","award":["17H04058"],"award-info":[{"award-number":["17H04058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Mol Morphol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00795-022-00344-7","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:02:32Z","timestamp":1672858952000},"page":"106-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment"],"prefix":"10.1007","volume":"56","author":[{"given":"Kaori","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Tamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiep","family":"Nguyen Canh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Le Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-0638","authenticated-orcid":false,"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"10","key":"344_CR1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","volume":"14","author":"CN Jenne","year":"2013","unstructured":"Jenne CN, Kubes P (2013) Immune surveillance by the liver. Nat Immunol 14(10):996\u20131006","journal-title":"Nat Immunol"},{"key":"344_CR2","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T (2017) Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol 410:75\u201397","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"344_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"2","key":"344_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3899\/jrheum.190084","volume":"47","author":"S Jamal","year":"2020","unstructured":"Jamal S, Hudson M, Fifi-Mah A, Ye C (2020) Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. J Rheumatol 47(2):166\u2013175","journal-title":"J Rheumatol"},{"issue":"1","key":"344_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR (2020) Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 72(1):315\u2013329","journal-title":"Hepatology"},{"issue":"6","key":"344_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.berh.2019.03.009","volume":"32","author":"K Ladak","year":"2018","unstructured":"Ladak K, Bass AR (2018) Checkpoint inhibitor-associated autoimmunity. Best Pract Res Clin Rheumatol 32(6):781\u2013802","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"344_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","volume":"141","author":"W Wang","year":"2017","unstructured":"Wang W, Lie P, Guo M, He J (2017) Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer 141(5):1018\u20131028","journal-title":"Int J Cancer"},{"issue":"6","key":"344_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68(6):1181\u20131190","journal-title":"J Hepatol"},{"issue":"6","key":"344_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM (2018) Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 31(6):965\u2013973","journal-title":"Mod Pathol"},{"issue":"10","key":"344_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/hepr.12931","volume":"47","author":"K Harada","year":"2017","unstructured":"Harada K, Hiep NC, Ohira H (2017) Challenges and difficulties in pathological diagnosis of autoimmune hepatitis. Hepatol Res 47(10):963\u2013971","journal-title":"Hepatol Res"},{"issue":"3","key":"344_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00795-014-0082-z","volume":"47","author":"K Abe","year":"2014","unstructured":"Abe K, Takahashi A, Nozawa Y, Imaizumi H, Hayashi M, Okai K et al (2014) The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol 47(3):162\u2013168","journal-title":"Med Mol Morphol"},{"issue":"4","key":"344_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35(4):529\u2013536","journal-title":"Invest New Drugs"},{"issue":"4","key":"344_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00795-008-0425-8","volume":"42","author":"N Kuroda","year":"2009","unstructured":"Kuroda N, Nakamura S, Miyazaki K, Inoue K, Ohara M, Mizuno K et al (2009) Chronic sclerosing pyelitis with an increased number of IgG4-positive plasma cells. Med Mol Morphol 42(4):236\u2013238","journal-title":"Med Mol Morphol"},{"issue":"4","key":"344_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00795-016-0143-6","volume":"49","author":"H Nguyen Canh","year":"2016","unstructured":"Nguyen Canh H, Harada K (2016) Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma. Med Mol Morphol 49(4):189\u2013202","journal-title":"Med Mol Morphol"},{"issue":"3 Pt 1","key":"344_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.1840120310","volume":"12","author":"JY Scoazec","year":"1990","unstructured":"Scoazec JY, Feldmann G (1990) Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus. Hepatology 12(3 Pt 1):505\u2013510","journal-title":"Hepatology"},{"issue":"1","key":"344_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1073\/pnas.78.1.129","volume":"78","author":"R Yoshida","year":"1981","unstructured":"Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O (1981) Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci USA 78(1):129\u2013132","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"344_CR17","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","volume":"17","author":"J Godin-Ethier","year":"2011","unstructured":"Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17(22):6985\u20136991","journal-title":"Clin Cancer Res"},{"issue":"24","key":"344_CR18","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ (2017) Discovery of IDO1 inhibitors: from bench to bedside. Can Res 77(24):6795\u20136811","journal-title":"Can Res"},{"issue":"5","key":"344_CR19","doi-asserted-by":"publisher","first-page":"e0217276","DOI":"10.1371\/journal.pone.0217276","volume":"14","author":"T Affolter","year":"2019","unstructured":"Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V et al (2019) Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE 14(5):e0217276","journal-title":"PLoS ONE"},{"issue":"4","key":"344_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ajhg.2012.08.010","volume":"91","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M et al (2012) Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 91(4):721\u2013728","journal-title":"Am J Hum Genet"},{"issue":"4","key":"344_CR21","first-page":"925","volume":"40","author":"K Harada","year":"2004","unstructured":"Harada K, Ohba K, Ozaki S, Isse K, Hirayama T, Wada A et al (2004) Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatology 40(4):925\u2013932","journal-title":"Hepatology"},{"issue":"6","key":"344_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55(6):653\u2013661","journal-title":"J Gastroenterol"},{"issue":"4","key":"344_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.hepres.2005.05.007","volume":"32","author":"H Takikawa","year":"2005","unstructured":"Takikawa H, Onji M (2005) A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res 32(4):250\u2013251","journal-title":"Hepatol Res"},{"issue":"3","key":"344_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28(3):671\u2013672","journal-title":"Ann Oncol"},{"issue":"4","key":"344_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1055\/s-0038-1667358","volume":"38","author":"BA Nadeau","year":"2018","unstructured":"Nadeau BA, Fecher LA, Owens SR, Razumilava N (2018) Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis 38(4):366\u2013378","journal-title":"Semin Liver Dis"},{"issue":"6","key":"344_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","volume":"36","author":"Y Zen","year":"2019","unstructured":"Zen Y, Yeh MM (2019) Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol 36(6):434\u2013440","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"344_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","volume":"66","author":"J Poisson","year":"2017","unstructured":"Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D et al (2017) Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol 66(1):212\u2013227","journal-title":"J Hepatol"},{"issue":"1\u20132","key":"344_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2012.10.009","volume":"429","author":"S Chen","year":"2012","unstructured":"Chen S, Corteling R, Stevanato L, Sinden J (2012) Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells. Biochem Biophys Res Commun 429(1\u20132):117\u2013123","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"344_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.4049\/jimmunol.0900408","volume":"183","author":"H Liu","year":"2009","unstructured":"Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA (2009) Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol 183(2):1022\u20131031","journal-title":"J Immunol"},{"issue":"8","key":"344_CR30","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.4049\/jimmunol.0904173","volume":"185","author":"H Ito","year":"2010","unstructured":"Ito H, Hoshi M, Ohtaki H, Taguchi A, Ando K, Ishikawa T et al (2010) Ability of IDO to attenuate liver injury in alpha-galactosyl ceramide-induced hepatitis model. J Immunol 185(8):4554\u20134560","journal-title":"J Immunol"},{"issue":"9","key":"344_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073404","volume":"8","author":"J Nagano","year":"2013","unstructured":"Nagano J, Shimizu M, Hara T, Shirakami Y, Kochi T, Nakamura N et al (2013) Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PLoS ONE 8(9):e73404","journal-title":"PLoS ONE"},{"issue":"1","key":"344_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0304-3835(92)90283-2","volume":"66","author":"BS Leung","year":"1992","unstructured":"Leung BS, Stout LE, Shaskan EG, Thompson RM (1992) Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells. Cancer Lett 66(1):77\u201381","journal-title":"Cancer Lett"},{"issue":"6","key":"344_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/hep.28122","volume":"62","author":"S Shimoda","year":"2015","unstructured":"Shimoda S, Hisamoto S, Harada K, Iwasaka S, Chong Y, Nakamura M et al (2015) Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology 62(6):1817\u20131827","journal-title":"Hepatology"},{"issue":"6","key":"344_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.20705","volume":"41","author":"K Harada","year":"2005","unstructured":"Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y (2005) Th1 cytokine-induced downregulation of PPAR gamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 41(6):1329\u20131338","journal-title":"Hepatology"},{"issue":"4","key":"344_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.510250402","volume":"25","author":"K Harada","year":"1997","unstructured":"Harada K, Van de Water WJ, Leung PS, Coppel RL, Ansari A, Nakanuma Y et al (1997) In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 25(4):791\u2013796","journal-title":"Hepatology"},{"issue":"6","key":"344_CR36","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/eji.202048589","volume":"51","author":"S Shimoyama","year":"2021","unstructured":"Shimoyama S, Kawata K, Ohta K, Chida T, Suzuki T, Tsuneyama K et al (2021) Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-gamma and CX3CL1 production in primary biliary cholangitis. Eur J Immunol 51(6):1519\u20131530","journal-title":"Eur J Immunol"},{"issue":"6","key":"344_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.510260604","volume":"26","author":"K Harada","year":"1997","unstructured":"Harada K, Ozaki S, Gershwin ME, Nakanuma Y (1997) Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 26(6):1399\u20131405","journal-title":"Hepatology"},{"key":"344_CR38","doi-asserted-by":"publisher","first-page":"793569","DOI":"10.1155\/2012\/793569","volume":"2012","author":"K Harada","year":"2012","unstructured":"Harada K, Nakanuma Y (2012) Cholangiopathy with respect to biliary innate immunity. Inter j hepatol 2012:793569","journal-title":"Inter j hepatol"}],"container-title":["Medical Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-022-00344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00795-022-00344-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-022-00344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T14:07:47Z","timestamp":1684246067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00795-022-00344-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1007\/s00795-022-00344-7","relation":{},"ISSN":["1860-1480","1860-1499"],"issn-type":[{"type":"print","value":"1860-1480"},{"type":"electronic","value":"1860-1499"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}